BLACKROCK GREATER EUROPE
INVESTMENT TRUST plc (LEI - 5493003R8FJ6I76ZUW55)
All information is at 31 October
2017 and unaudited.
Performance at month end with net income reinvested
|
One
Month |
Three
Months |
One
Year |
Three
Years |
Launch
(20 Sep 04) |
Net asset value
(undiluted) |
1.8% |
5.8% |
19.9% |
57.8% |
346.0% |
Net asset value*
(diluted) |
1.8% |
5.8% |
19.9% |
57.9% |
346.4% |
Share price |
3.9% |
8.4% |
21.1% |
61.3% |
335.8% |
FTSE World Europe ex
UK |
1.5% |
3.3% |
19.9% |
51.0% |
248.2% |
* Diluted for treasury shares and subscription shares.
Sources: BlackRock and Datastream
At month end
Net asset value
(capital only): |
347.49p |
Net asset value
(including income): |
351.80p |
Net asset value
(capital only)1: |
347.49p |
Net asset value
(including income)1: |
351.80p |
Share price: |
341.00p |
Discount to NAV
(including income): |
3.1% |
Discount to NAV
(including income)1: |
3.1% |
Net gearing: |
2.8% |
Net
yield2: |
1.6% |
Total assets
(including income): |
£335.2m |
Ordinary shares in
issue3: |
95,295,953 |
Ongoing
charges4: |
1.10% |
1 Diluted for treasury shares.
2 Based on a final dividend of 3.70p per share and an interim
dividend of 1.75p per share for the year ended 31 August 2017.
3 Excluding 15,032,985 shares held in treasury.
4 Calculated as a percentage of average net assets and using
expenses, excluding interest costs, after relief for taxation, for
the year ended 31 August 2017.
Sector
Analysis |
Total
Assets
(%) |
|
Country
Analysis |
Total
Assets
(%) |
Industrials |
29.3 |
|
France |
17.0 |
Health Care |
17.5 |
|
Switzerland |
16.0 |
Consumer Goods |
16.0 |
|
Germany |
14.0 |
Consumer Services |
13.4 |
|
Netherlands |
13.0 |
Technology |
9.4 |
|
Denmark |
12.1 |
Financials |
7.9 |
|
Sweden |
8.7 |
Oil & Gas |
4.2 |
|
Belgium |
5.7 |
Basic Materials |
3.5 |
|
Russia |
4.2 |
Net current
liabilities |
(1.2) |
|
Spain |
3.6 |
|
----- |
|
Finland |
2.6 |
|
100.0 |
|
Israel |
1.7 |
|
===== |
|
Greece |
1.6 |
|
|
|
Ukraine |
1.0 |
|
|
|
Net current
liabilities |
(1.2) |
|
|
|
|
----- |
|
|
|
|
100.0 |
|
|
|
|
===== |
Ten Largest Equity
Investments |
|
|
Company |
Country |
%
of
Total Assets |
SAP |
Germany |
4.7 |
Unilever |
Netherlands |
4.7 |
Lonza Group |
Switzerland |
4.2 |
Fresenius Medical
Care |
Germany |
3.9 |
Compagnie Financière
Richemont |
Switzerland |
3.8 |
ASML |
Netherlands |
3.7 |
Danske Bank |
Denmark |
3.7 |
RELX |
Netherlands |
3.6 |
Industria De Dise |
Spain |
3.6 |
DSV |
Denmark |
3.5 |
Commenting on the markets, Stefan
Gries, representing the Investment Manager noted:
During the month, the Company’s NAV rose by 1.8% and the share
price increased by 3.9%. For reference, the FTSE World Europe ex UK
Index returned 1.5% during the period.
Over October, resources including oil & gas and basic materials
saw strong returns. Several defensive sectors, which are less
geared to the economic cycle, such as health care and telecoms
lagged the market.
The European Central Bank (‘ECB’) announced an extension to its
Quantitative Easing (‘QE’) programme to September 2018, although purchases will be cut
from €60bn a month to €30bn from January
2018. ECB president Mario
Draghi stressed that the move was not a ‘taper’ but merely a
‘downsize’ as a degree of monetary stimulus remained necessary
while inflation is below the ECB’s target of close to 2%.
Political risk heightened given that Catalonia declared
independence from Spain, the
Italian regions of Lombardy and
Veneto voted on greater regional
independence and the Austrian far-right Freedom Party started talks
to form a coalition government.
However, the economic picture remains robust with the European
Commission’s monthly eurozone economic sentiment survey rising in
October for the fifth consecutive month to reach its highest level
since the start of 2001, showing almost no impact from the Catalan
crisis.
The Company outperformed the reference index over the month. Sector
allocation was the primary driver of returns; stock selection was
marginally negative.
On a sector basis the stronger performance came from the lower
allocation to the financials sector, and in particular banks. The
sector underperformed following the ECB’s announcement to cut the
amount of QE purchases whilst extending the time frame upon which
they will make such purchases. The latter proved more dovish than
the market expected, leading to share price pressure on the
sector.
The higher allocation to technology was also beneficial to returns,
whilst the greater allocation to health care detracted as the
sector suffered poor results releases for the third quarter.
Over the period the poorest performing position was Israeli listed
Teva Pharmaceuticals. A competitor of the company, Mylan, received
earlier than expected approval for their generic version of
Copaxone 20 and 40mg, in direct competition with Teva’s largest
drug.
Luxury businesses Remy Cointreau and
Kering both contributed positively to performance. Remy reported a
6.2% year-on-year sales growth for the third quarter beating market
expectations. Kering was the Company’s top contributing stock over
the month after third quarter results showed a continuation of very
strong operating trends. The Gucci brand recorded organic sales
growth of 49%, significantly above consensus expectations and the
company are now guiding to full year margins of 33%.
Whilst the overweight allocation to health care detracted overall,
a position in Straumann rallied as it reported 16% organic sales
growth year-on-year for the third quarter, raising its full year
guidance from low teens to 13-15%.
Stock selection within industrials proved disappointing over
October. Finnish shipbuilding company, Wartsila, saw share price
pressure as Q3 results underwhelmed. We remain confident in holding
the stock as it continues to enjoy strong order intake
momentum.
Outlook
The increasing breadth of the global economic expansion continues
to provide a positive backdrop for European corporate earnings. The
pick-up in sales growth has led to a clear recovery in profits
feeding into a rebound in capex spending. With inflation remaining
well below target we expect ECB policy to remain accommodative.
Long term, with structural and demographic drivers keeping a lid on
inflation in the euro area, we believe we can enjoy a sustained
period of growth without the need for substantial increases in
interest rates. In terms of valuation, European equities are
relatively inexpensive when compared with fixed income and
especially in terms of dividend yield.
Improving demand growth, a low cost of capital and broad-based
resilience in economic sentiment, underpin a positive stance for
European equity markets.
14 November 2017
ENDS
Latest information is available by typing www.brgeplc.co.uk on the
internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on
Topic 3 (ICV terminal). Neither the contents of the Manager’s
website nor the contents of any website accessible from hyperlinks
on the Manager’s website (or any other website) is incorporated
into, or forms part of, this announcement.